Asker Healthcare Group AB (FRA:I88) Q2 2026 Earnings Call Highlights: Strong EBITDA Growth and ...

This article first appeared on GuruFocus .

Release Date: July 21, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript .

Positive Points

• Asker Healthcare Group AB ( FRA:I88 ) reported a 24% adjusted EBITDA growth, with 6% being organic.

• The company achieved a 10% EBITDA margin for the quarter, marking a 0.5 percentage point increase from the previous year.

• Net sales increased by 18% to $4.7 billion, with 5% of this growth being organic.

• The company received an AAA rating from MSCI for ESG and sustainability efforts, aiding in winning tenders in Northern Europe.

• Asker Healthcare Group AB ( FRA:I88 ) has a strong M&A pipeline, having completed four acquisitions year-to-date, and is ahead of its annual acquisition targets.

Negative Points

• The company's leverage ratio is slightly elevated at 2.37 times due to large cash outflows, though it remains within target limits.

• There was a temporary increase in working capital due to double inventory costs related to the new warehouse in Gothenburg.

• The company discontinued an acquisition in Denmark due to prolonged competition authority processes.

• There are anticipated low single-digit million SEK costs related to double manning during the warehouse transition.

• The organic growth in the West region was lower than expected, attributed to a strong prior year comparison.

Q & A Highlights

• Warning! GuruFocus has detected 2 Warning Sign with FRA:I88.

• Is FRA:I88 fairly valued? Test your thesis with our free DCF calculator.

Q: Can you provide more details on the strong organic growth of 10% year-over-year in the North region? Are there any one-off related larger orders? A: No, there are no big one-off orders similar to what we had in 2024. The growth is more of a steady, solid, strong base performance from the region rather than anything extraordinary. We encourage looking at the rolling 12-month performance rather than focusing on individual quarters. (CFO Thomas Moss)

Q: Regarding the earn-out payments for 2027, can you elaborate on how much larger they can potentially be, and will they be paid out in Q2? A: The vast majority of earn-out payments will be paid out in Q2, as we wait for fully audited annual reports. The payments for 2027 are for companies that come to the end of their earn-out in December 2026. The figure might be 10% higher or lower, but it won't dramatically change due to the established ceiling on maximum earn-out payments. (CFO Thomas Moss)

Q: Can you provide an update on the new warehouse in Gothenburg? Are there any anticipated effects on volumes or earnings? A: We don't expect any impact on volumes or operational activities. The plan is to gradually ramp up operations through Q3 and Q4, with full operational status expected in the first half of 2027. There will be low single-digit million SEK in double manning costs, primarily in Q4, and a temporary effect on working capital. (CFO Thomas Moss)